EUCTR2008-007645-31-DE进行中（未招募）不适用
Freiburger Studie zur Behandlung von Primären ZNS-Lymphomen bei Patienten über 65 Jahre: Methotrexat-basierte Chemo-Immuntherapie mit anschließender Erhaltungstherapie- PRIMAIN-Studie - - PRIMAI
niversity Medical Center Freiburg0 个研究点开始时间: 2009年3月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •patients with newly diagnosed primary Non-Hodgkin Lymphoma (NHL) of the central nervous system (CNS), histologically confirmed
- •- patients aged over 65 years
- •- patient legally competent, physically or mentally able of giving consent
- •- written, signed and dated informed consent of the patient (if legally competent) or of the legal representative (if patient legally incompetent) after detailed information according to international guidelines.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- patients with systemic lymphoma manifestations
- •- HIV seropositive patients
- •- patients with severe pulmonary, cardial, hepatic or renal damage, which could seriously impair the feasability of cytoreductive therapy in a life-threatening way
- •-patients with severe infections, which could seriously impair the feasability of cytoreductive therapy in a life-threatening way
- •- patients with the following haematologic parameters: neutrophile count < 2.000/µl, platelet count < 100.000/µl
- •- patients with known intolerance against study medications or ingredients
- •- pregnancy or lactation period
- •-participation in another within the last 30 days prior to the begin or parallel to this study
- •- known or current alcohol or drug abuse
研究者
相似试验
进行中（未招募）
不适用
Freiburger ZNS-NHL StudieTherapie für Patienten mit primären Non-Hodgkin Lymphomen des ZNS – Sequentielle Hochdosis-Chemotherapie mit autologer peripherer Blutstammzelltransplantation - Freiburger ZNS-NHL-Studieprimary Non-Hodgkin Lymphoma of the Central Nervous System (PCNSL), histologically confirmedAge: 18 - 65 yearsMedDRA version: 16.1Level: PTClassification code 10029614Term: Non-Hodgkin's lymphoma unspecified histology aggressive stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-000615-99-DEniversity Medical Center Freiburg
已完成
2 期
Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell PlantatioPrimary Non Hodgkin Lymphoma of the Central Nervous SystemC83.3Diffuse large B-cell lymphomaDRKS00003748niversitätsklinikum FreiburgAbt. Med 1Hämatologie / Onkologie120
进行中（未招募）
1 期
A Phase II Pilot Study to Assess Safety and Efficacy of Sodium Valproate in Adults with McArdle DiseaseMcArdle disease (Glycogen storage disease type V, GSDV). The condition is an inherited disorder of skeletal muscle that causes exercise intolerance. The condition can give way to potential rhabdomyolysis which can cause acute renal failure and from middle age muscle wasting and weakness. Affected patients are unable to produce lactate during ischaemic exercise due to a congenital lack of the enzyme muscle glycogen phosphorylase which is essential for glycogen metabolism.MedDRA version: 16.1 Level: LLT Classification code 10026969 Term: McArdle's disease System Organ Class: 100000004850EUCTR2012-002933-12-GBniversity College London,8
招募中
2 期
Radiation treatment prior to surgery for local spine metastasisACTRN12615001031550Epworth HealthCare20
尚未招募
不适用
To study the role of Zinc combined with standard treatment for COVID-19CTRI/2020/07/026340Ramen Goel